An Australian team developed a decision model for testing asymptomatic relatives of patients with dilated cardiomyopathy to assess the cost effectiveness of testing.
The partners are aiming to broaden the applicability of Genetic Technologies' BrevaGenplus breast cancer risk assessment test.
The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.
